The 6 most recent market catalysts affecting $OABI, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12
Leerink Partners analyst Puneet Souda has maintained an 'Outperform' rating on OmniAb (OABI) and raised the price target from $10 to $12. This action reflects an analyst's updated …
Oct 7, 2026
Corporate Catalyst
Bullish
Impact 55
StoneX Maintains Buy on OmniAb, Raises Price Target to $6
StoneX analyst Robert Wasserman maintained a 'Buy' rating on OmniAb (OABI) and raised the price target from $4 to $6. This action signals increased confidence from a reputable fina…
Aug 18, 2026
Macro/Central Bank
Bearish
Impact 55
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
The filing details a mixed trading day for US stocks, with the S&P 500 slightly down. Key economic data points include a modest rise in the NAHB/Wells Fargo Housing Market Index an…
Aug 17, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Omniab Stock Rallying After Eli Lilly Deal?
OmniAb (OABI) announced a global collaboration and license agreement with Eli Lilly (LLY) for an ion channel program. This is a significant positive catalyst for OmniAb, as it incl…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
OmniAb Raises FY2026 Sales Guidance from $28.000M-$33.000M to $32.000M-$36.000M vs $30.807M Est
OmniAb (OABI) has announced an upward revision to its FY2026 sales guidance, moving from an initial range of $28.000M-$33.000M to a new range of $32.000M-$36.000M. This change is s…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 95
OmniAb Q2 EPS $(0.05) Beats $(0.12) Estimate, Sales $13.415M Beat $4.693M Estimate
OmniAb (OABI) announced Q2 results that significantly surpassed analyst expectations. The company reported a narrower loss per share than anticipated and, more notably, sales that …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.